After years of emotional and legislative debate, the controversial “right-to-try” concept of expanding access to experimental medicines became law last month. But the authors of a new study suggest that the effort, which is designed to sideline the Food and Drug Administration, may have been unnecessary, because a previous regulatory program appeared to be working well.
How so?
About the Author Reprints
